Citations

Clear

3138 citation(s) found for "Smith, AM".

Hypoglycemia in Prospective Multicenter Study of Pregnancies with Pre-Existing Type 1 Diabetes on Sensor-Augmented Pump Therapy: The LOIS-P Study
Kaur, Ravinder Jeet , Özaslan, Başak , Pinsker, Jordan E. , Trinidad, Mari Charisse, O’Malley, Grenye , Desjardins, Donna, Castorino, Kristin , Levister, Camilla, Reid, Corey, McCrady-Spitzer, Shelly , Ogyaadu, Selassie, Church, Mei Mei , Piper, Molly, Kremers, Walter K. , Rosenn, Barak, Dassau, Eyal , Kudva, Yogish C. , Doyle, Francis J , Dassau, Eyal , Kudva, Yogish C. , Kremers, Walter K , Smith, Byron H. , Doyle, Francis J. , Levy, Carol J.

Mayo Clinic

Diabetes Technology & Therapeutics | March 29, 2022 | Volume: 24 | Issue: 8 | Pages: 544-555

10.1089/dia.2021.0479 | PMID 35349353 Get It

Background: Pregnancies in type 1 diabetes are high risk, and data in the United States are limited regarding continuous glucose monitoring (CGM)-based hypoglycemia throughout pregnancy while on sensor-augmented insulin pump therapy. Materials and Methods: Pregnant women with type 1 diabetes in the LOIS-P Study (Longitudinal Observation of Insulin use and glucose Sensor metrics in Pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps) were enrolled before 17 weeks gestation at three U.S. centers and we used their personal insulin pump and a study Dexcom G6 CGM. We analyzed data of 25 pregnant women for CGM hypoglycemia based on international consensus guidelines for percentage time <63 and 54 mg/dL, hypoglycemic events and prolonged hypoglycemia events for 24-h, daytime, and overnight periods, and severe hypoglycemia (SH) episodes. Results: For a 24-h period, biweekly median percentage of time <63 mg/dL ranged from 0.8% at biweek 4–5 to 3.7% at biweek 14–15 with high variability throughout pregnancy. Median percentage of time <63 and 54 mg/dL was higher overnight than daytime ( P < 0.01). Hypoglycemic events occurred throughout the pregnancy, ranged 1–4 events per 2 weeks, significantly decreased after the 20th week, and occurred predominantly during daytime ( P < 0.01). For overnight period, hypoglycemia and events were more concentrated from 12 to 3 am. Seven prolonged hypoglycemia events without any associated SH occurred in four participants (16%), primarily overnight. Three participants experienced a single episode of SH. Conclusions: Our results suggest a higher overall risk of hypoglycemia throughout pregnancy during the overnight period with continued daytime risk of hypoglycemic events in pregnancies complicated by type 1 diabetes.
Mapping multiregional image-localized biopsies to MRI habitats reveal biologically significant glioma tissue states and patterns of cellular subpopulations
Curtin, Lee , Bond, Kamila M. , Jackson, Pamela , Hawkins‐Daarud, Andrea , Velez, Sebastian, Shakir, Neha, Urcuyo, Javier , León, Gustavo De , Singleton, Kyle , Langworthy, Jazlynn , Clark-Swanson, Kamala R., Lassiter-Morris, Yvette, Paulson, Lisa, Sereduk, Christopher, Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi Prasad, Smith, Kris A. , Donev, Kliment , Tran, Nhan L. , Hu, Leland , Plaisier, Christopher, Mrugała, Maciej M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Tran, Nhan L , Velez, Sebastian, Shakir, Neha, Leon, Gustavo De, Clark-Swanson, Kamala R., Lassiter-Morris, Yvette, Paulson, Lisa, Sereduk, Chris , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie C. , Plaisier, Christopher, Anderson, Alexander R A , Grinband, Jack , Al‐Dalahmah, Osama , Rubin, Joshua B

Mayo Clinic

No container title available | March 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.03.23.485500 Get It

Abstract Background Magnetic Resonance Imaging (MRI) is the mainstay for neurosurgical oncology but not for informing us about glioma biology. An obstacle to developing MR-based glioma biomarkers is the absence of rigorous correlation between MRI features and glioma biology as assessed in multi-regional biopsies, within and across patients. Methods We directly addressed this obstacle by collating a unique cohort of 202 MRI-localized biopsies from 58 patients. We define a low-dimensional transcriptional pseudotime continuum along which heterogeneous high-grade glioma (HGG) samples organize both within and across patients. Results We observe three polarized transcriptional tissue states: infiltrated brain, immune/inflammatory, and proliferative associated with patterns of cohabitation of cellular subpopulations. The states and deconvolved populations show correlation with enhancement status on T1Gd MRI. Moreover, discrete MRI habitats, regions sharing common imaging features, defined as combinations of high or low signal intensity across multiparametric MRI revealed 14 MRI habitats. We order the MRI habitats according to the average pseudotime on the transcriptional continuum. We find that MRI habitats with low pseudotime (associated with early tumor development and diffusely invaded brain tissue) localized at the periphery of the tumor whilst high pseudotime either proliferative or immune/inflammatory states were towards the core of the lesion. We find that composition of MRI habitats are impacted by MGMT status and patient sex. Conclusion This suggests that ongoing aggregation of MRI-localized biopsies may augment our projection of biology onto MRI habitats to support tracking of the evolution of cellular ecologies within and across each patient’s tumor over time. Key Points Trajectory inference of HGG samples reveals a continuum connecting three polarized tissue states reflecting transitions in cellular population ecologies and gene set enrichment Combining multiparametric MRI features into regional MRI habitats reveal clinically-distinct patterns of cell co-habitation and tissue state MGMT methylation status shifts the cellular patterns of cohabitation within MRI habitats Importance of the Study Regional heterogeneity is a defining characteristic of high-grade glioma (HGG). Mapping the transcriptomic biology of multiregionally sampled MRI-localized biopsies from high-grade gliomas onto a low-dimensional space reveals a continuum between three primary tissue states: infiltrated brain, immune/inflammatory, and proliferative. Each state is associated with distinct cell cohabitation ecologies. Transitions between the tissue states coordinate with changes in tumor composition, revealing potential direct connections between tumor biology shifts and their manifestation on clinical imaging.
A framework for examining patient attitudes regarding applications of artificial intelligence in healthcare
Richardson, Jordan , Smith, Cambray , Barry, Barbara , Sharp, Richard R. , Richardson, Jordan P , Curtis, Susan , Pacyna, Joel, Zhu, Xuan , Barry, Barbara , Sharp, Richard R , Pacyna, Joel E.

Mayo Clinic

DIGITAL HEALTH | March 25, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762210890

10.1177/20552076221089084 | PMID 35355806 Get It

Background While use of artificial intelligence (AI) in healthcare is increasing, little is known about how patients view healthcare AI. Characterizing patient attitudes and beliefs about healthcare AI and the factors that lead to these attitudes can help ensure patient values are in close alignment with the implementation of these new technologies. Methods We conducted 15 focus groups with adult patients who had a recent primary care visit at a large academic health center. Using modified grounded theory, focus-group data was analyzed for themes related to the formation of attitudes and beliefs about healthcare AI. Results When evaluating AI in healthcare, we found that patients draw on a variety of factors to contextualize these new technologies including previous experiences of illness, interactions with health systems and established health technologies, comfort with other information technology, and other personal experiences. We found that these experiences informed normative and cultural beliefs about the values and goals of healthcare technologies that patients applied when engaging with AI. The results of this study form the basis for a theoretical framework for understanding patient orientation to applications of AI in healthcare, highlighting a number of specific social, health, and technological experiences that will likely shape patient opinions about future healthcare AI applications. Conclusions Understanding the basis of patient attitudes and beliefs about healthcare AI is a crucial first step in effective patient engagement and education. The theoretical framework we present provides a foundation for future studies examining patient opinions about applications of AI in healthcare.
BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
Spikes, Leslie , Eggert, Michael, Johri, Shilpa , Joly, Joanna M., Mehta, J.P. , Palevsky, Harold I. , Ramani, Gautam , Restrepo‐Jaramillo, Ricardo, Sahay, Sandeep , Shah, Trushil , Miceli, Melissa, Smith, Peter , Shapiro, Shelley, Spikes, Leslie A , Sahay, Sandeep , Bajwa, Abubakr A. , Burger, Charles D. , Desai, Sapna V., El‐Kersh, Karim , Fisher, Micah R., Deng, Chunqin

Mayo Clinic

Pulmonary Circulation | March 23, 2022 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/pul2.12063 | PMID 35514770 Get It

AbstractInhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment for nebulizer preparation, maintenance, and treatment. A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study was to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in patients currently treated with treprostinil inhalation solution. Fifty‐one patients on a stable dose of treprostinil inhalation solution enrolled and transitioned to TreT at a corresponding dose. Six‐minute walk distance (6MWD), device preference and satisfaction (Preference Questionnaire for Inhaled Treprostinil Devices [PQ‐ITD]), PAH Symptoms and Impact (PAH‐SYMPACT®) questionnaire, and systemic exposure and pharmacokinetics for up to 5 h were assessed at baseline for treprostinil inhalation solution and at Week 3 for TreT. Adverse events (AEs) were consistent with studies of inhaled treprostinil in patients with PAH, and there were no study drug‐related serious AEs. Statistically significant improvements occurred in 6MWD, PQ‐ITD, and PAH‐SYMPACT. Forty‐nine patients completed the 3‐week treatment phase and all elected to participate in an optional extension phase. These results demonstrate that, in patients with PAH, transition from treprostinil inhalation solution to TreT is safe, well‐tolerated, and accompanied by statistically significant improvements in key clinical assessments and patient‐reported outcomes with comparable systemic exposure between the two formulations at evaluated doses (trial registration: clinicaltrials.gov identifier: NCT03950739).
Late Complications of COVID-19
Roden, Anja C. , Johnson, Tucker F. , Aubry, Marie Christine, Butt, Yasmeen M. , Maleszewski, Joseph J. , Larsen, Brandon T. , Tazelaar, Henry D. , Khoór, András , Moua, Teng , Jenkins, Sarah M. , Moyer, Ann M. , Yi, Eunhee , Bois, Melanie C. , Boland, Jennifer M. , Lo, Ying‐Chun , Tazelaar, Henry D. , Smith, Maxwell L. , Yi, Eunhee S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 23, 2022 | Volume: 146 | Issue: 7 | Pages: 791-804

10.5858/arpa.2021-0519-sa | PMID 35319744 Get It

Context.— Studies of lungs in patients with COVID-19 have focused on early findings. Objective.— To systematically study histopathologic and imaging features and presence of SARS-CoV-2 RNA in lung tissue from patients in later stages of COVID-19. Design.— Autopsies, explants, surgical lung biopsies, transbronchial biopsies, cryobiopsies, and needle biopsies from patients with COVID-19 whose onset of symptoms/confirmed diagnosis was more than 28 days before the procedure were studied. Available images were reviewed. Reverse transcription droplet digital polymerase chain reaction for SARS-CoV-2 RNA was performed on lung tissue. Results.— Of 44 specimens (43 patients; median age, 59.3 years; 26 [60.5%] male) features of acute lung injury (ALI) were seen in 39 (88.6%), predominantly organizing pneumonia and diffuse alveolar damage, up to 298 days after onset of COVID-19. Fibrotic changes were found in 33 specimens (75%), most commonly fibrotic diffuse alveolar damage (n = 22) and cicatricial organizing pneumonia (n = 12). Time between acquiring COVID-19 and specimen was shorter in patients with diffuse ALI (median, 61.5 days) compared with patients with focal (140 days) or no ALI (130 days) (P = .009). Sixteen (of 20; 80%) SARS-CoV-2 reverse transcription droplet digital polymerase chain reaction tests were positive, up to 174 days after COVID-19 onset. Time between COVID-19 onset and most recent computed tomography in patients with consolidation on imaging was shorter (median, 43.0 days) versus in patients without consolidation (87.5 days; P = .02). Reticulations were associated with longer time to computed tomography after COVID-19 onset (median, 82 versus 23.5 days; P = .006). Conclusions.— ALI and SARS-CoV-2 RNA can be detected in patients with COVID-19 for many months. ALI may evolve into fibrotic interstitial lung disease.
Reply to A. Smith et al
Fontana, Elisa , Meyers, Jeffrey P., André, Thierry , Ben‐Aharon, Irit , Shi, Qian , André, Thierry , Shi, Qian , Fontana, Elisa

Mayo Clinic

Journal of Clinical Oncology | March 22, 2022 | Volume: 40 | Issue: 16 | Pages: 1844-1846

10.1200/jco.22.00246 | PMID 35316071 Get It

Abstract W MP84: Erythropoietin Inhibits Oxidation of Tetrahydrobiopterin and Restores Bioavailability of Endothelial Nitric Oxide in Cerebral Microvessels of Hph-1 Mice
Santhanam, Anantha Vijay R., Katušić, Zvonimir S. , d’Uscio, Livius V. , Smith, Leslie A

Mayo Clinic

Stroke | March 20, 2022 | Volume: 45 | Issue: suppl_1 | Pages: No page available

10.1161/str.45.suppl_1.wmp84 Get It

Background: While reported neuroprotective effects of erythropoietin (EPO) make it an appealing candidate for its evaluation in protection of neurovascular unit during cerebrovascular or neurodegenerative disorders, effects of EPO on cerebral microvessels, the vascular component of neurovascular unit, have not been studied to date. The present study was designed to determine the effects of EPO in cerebral microvessels derived from wild-type mice and also from hph-1 mice, a genetic mouse model of BH4 deficiency. Methods: Hph-1 mice and wild-type littermates (C57BL/6 background) were administered recombinant human EPO (1000 U/kg/day) intraperitoneally for 3 days. Following treatment, mice were killed by injection of an overdose of pentobarbital, brains were removed and cerebral microvessels were isolated. Results: Treatment of wild-type mice with EPO did not affect BH4 bioavailability, superoxide anion production or basal cGMP levels. We have reported that cerebral microvessels of hph-1 mice demonstrated reduced bioavailability of BH4, increased production of superoxide anions and impaired endothelial NO/cGMP signaling. Treatment of hph-1 mice with EPO attenuated the levels of 7,8-dihydrobiopterin (7,8-BH2; P<0.05, n=5), oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8-BH2 (P<0.05, n=5), indicative of increased bioavailability of BH4 for eNOS activation. Increased superoxide anion production in cerebral microvessels of hph-1 mice were attenuated by EPO treatment (P<0.05, n=5). While eNOS expression remained unchanged, levels of cGMP were significantly increased on EPO treatment in hph-1 mice (P< 0.05, n=6). Furthermore, EPO treatment selectively increased expression of manganese superoxide dismutase. Conclusion: The ability of EPO to attenuate oxidative stress and restore bioavailability of endothelial NO in cerebral microvessels may help to explain mechanisms responsible for cerebrovascular protective effects of EPO.
Abstract 11388: Multimorbidity Moderates Changes in Peak Oxygen Uptake in Cardiac Rehabilitation Patients
Suarez, Audry Chacin, Taylor, Jenna L. , Bonikowske, Amanda R. , Squires, Ray W. , Olson, Thomas P. , Taylor, Jenna L , Chacin‐Suarez, Audry , Medina‐Inojosa, José R. , Smith, Joshua R. , Thomas, Randal J.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.11388 Get It

Introduction: Patients undergoing cardiac rehabilitation (CR) exhibit various degrees of illness severity and high prevalence of chronic conditions (CC). Cardiorespiratory fitness (CRF) is a key predictor of outcomes in patients with cardiovascular disease. Participation in CR is associated with increased CRF, reduced future cardiovascular events, and mortality. Peak oxygen uptake (VO 2 ) is the gold-standard method to evaluate CRF; however, the burden of multimorbidity and its impact on CRF improvement has not been extensively studied. Methods: We included 618 patients who were ≥ 18 years old and underwent cardiopulmonary exercise testing prior to and after CR at Mayo Clinic. Using the Rochester Epidemiology Project records- linkage system, we assessed the prevalence of 18 CC defined by the US Department of Health and Human Services. To evaluate changes in peak VO 2 in patients with multimorbidity (categorized as ≥6 CC), we created logistic regression models adjusting for age, sex, and baseline peak VO 2 . Results: Mean age was 61.5 ± 11.0 years and 75.5% were male. Most patients (81.2%) attended ≥18 CR sessions. Half (50.4%) of patients had at least 6 CC (median 6; range 0-13). Overall, peak VO 2 at baseline was 20.7 ± 6.3 mL/kg per min and the percent change in peak VO 2 following CR was 11.4% ± 21.6%, Figure 1A . Multimorbidity was associated with lower improvement in peak VO 2 following CR compared to patients with <6 CC (7.5% vs 11.4%, p=0.0001). Furthermore, across categories of CRF improvement (i.e., 1%, 5%, and 10% percent change in peak VO 2 ) lower multimorbidity was associated with a 1.5-2-fold increase in CRF when compared to those with higher multimorbidity (≥6 CC), Figure 1B . Conclusions: Patients entering CR have a high multimorbidity burden. Our results suggest that multimorbidity in CR patients attenuates improvement in peak VO 2 . Individualized interventions should focus on managing and reducing multimorbidity to minimize the negative impact on CRF improvement.
Abstract 10680: Unsupervised Machine Learning Clustering Identifies Phenotypes of Optimal Candidates in Mitraclip Patients
Wu, Han-Lun, Seri, Amith Reddy , Shanbhag, Anusha , Rayfield, Corbin, Wang, Yuxiang , Smith, S. M. , Fortuin, F. David , Sweeney, John P., Eleid, Mackram F. , Rihal, Charanjit S. , Holmes, David R. , Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Shen, Win K., Patel, Bhavik N. , Chao, Chieh‐Ju , Smith, Sean, Alkhouli, Mohamad , Rihal, Charanjit S. , Arsanjani, Reza

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10680 Get It

Introduction: Unsupervised machine learning (ML) can provide insight into a dataset without significant expert time for annotation and labeling, but was never used to assess the heterogeneous MitraClip population. Hypothesis: We hypothesized that unsupervised k-means ML could identify prognostically-distinct phenogroups in MitraClip patients without a priori knowledge of the dataset. Methods: Patients who underwent MitraClip (June 2014-September 2020) at Mayo Clinic sites were identified from the Mayo institutional NCDR database for baseline and follow-up data. Variables with ≥ 50% missing data were excluded. A k-means algorithm was used for clustering analysis. Input variables were grouped according to 4 distinct k-means determined clusters. Kaplan-Meier survival analysis was used to assess the survival of each cluster. Results: A total of 389 consecutive patients were included in the final analysis, and 95 unique variables were used. The mean age was 80.3±8.7 years; 256 (65.8%) were male. The mean STS MV Replace score was 9.1±5.7. Fifty-five (14.5%) patients died during the mean follow duration (185 days). Kaplan-Meier analysis showed significant survival differences among clusters (Figure 1). The cluster (cluster 2, n=120) with best survival performance (all-cause mortality 3.3%) had features of non-calcified mitral leaflets, nonischemic cardiomyopathy, and less than moderate tricuspid regurgitation. Cluster 3 (n=66) had the worst survival performance (all-cause mortality 27.3%) and opposite features than cluster 2. Conclusions: Unsupervised ML can identify distinct phenotype clusters with prognostic significance in MitraClip patients. Patients with non-calcified mitral leaflets, nonischemic cardiomyopathy, and less than moderate tricuspid regurgitation are intrinsically different from other MitraClip patients and should be considered the potential optimal candidates.
Abstract 10648: The Presence of Iatrogenic Atrial Septal Defect Does Not Affect the Right Ventricular Strain Function in Patients with More Than Moderate Tricuspid Regurgitation
Seri, Amith Reddy , Fennellly, Evelyn, Campany, Megan , Kenyon, Courtney , Fath, Ayman R. , Smith, Sean B. , Buckner‐Petty, Skye , Rayfield, Corbin, Fortuin, David, Sweeney, John P., Mackram, Eleid F, Rihal, Charanjit S. , Pollak, Peter , Sabbagh, Abdallah El , Chao, Chieh‐Ju , Alkhouli, Mohamad , Rihal, Charanjit S. , Arsanjani, Reza

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10648 Get It

Background/Introduction: More than moderate tricuspid regurgitation (TR) at baseline is associated with worse outcome in MitraClip patients. The presence of iatrogenic ASD (iASD) may cause right-sided volume overload and lead to adverse events. However, the real effects of iASD are not well-investigated in these patients who are vulnerable to right-sided volume overload. Methods: Patients with more than moderate TR who underwent a successful MitraClip procedure in the period from June 2014 to September 2020 were identified from the Mayo institutional NCDR database. Follow-up transthoracic echocardiography (TTE) at about 1 year after the procedure was used to determine the presence of iASD, and speckle-tracking strain analysis was done. Patients were grouped according to the presence of iASD (iASD+ group vs. iASD- group) for statistical analysis. Results: A total of 141 consecutive patients were included for the final analysis (iASD+ group n=44 and iASD- group n=97). The mean age was 79.3 ± 8.8 years, and 72.3% were male. Follow-up echocardiography and speckle-tracking strain data did not show a significant difference in either left or right ventricular function in conventional echocardiographic parameters and strain. LA reservoir strain (13.7 ± 6.9 vs 11.5±7.5, P=0.0418) was the only parameter with significant difference among the two groups. Details are summarized in Table 1 . Conclusion: The presence of iASD can decompress the left atrium, but does not affect left or right ventricular strain function in MitraClip patients with more than moderate baseline TR.